feature

Kamarisz and USMARI enter partnership

KUALA LUMPUR: Medical services provider Kamarizs Medicare Sdn Bhd has partnered with USMARI Research & Innovation Centre for collaboration aims to foster evidence-based research and contribute to the well-being of the community.

Kamarizs Medicare director Datin Dr Suhaila Sujani said the key objective of the collaboration is to enhance the existing relationship between the company and USMARI in the realm of clinical research.

Notably, Suhaila said Kamarizs Medicare has completed two clinical studies in partnership with USMARI, and two ongoing studies focus on pigmentation and the safety and efficacy of its product.

"This collaboration has already yielded fruitful results, with our first research project accepted for publication in the International Journal of Cosmetic Medicine in Korea.

"This milestone underscores our commitment to conducting rigorous research and creating more awareness in the aesthetic medicine industry," she told Business Times in an interview.

Suhaila also said the collaboration serves as a testament to the importance of evidence-based research in ensuring the safety and effectiveness of its products that ultimately benefit the community.

She highlighted that one of the advantages of evidence-based clinical research is that it provides results rooted in standard measurements and devoid of potential bias.

"These findings have far-reaching implications for the community, as they can instill confidence in the safety and efficacy of our products being researched," she said.

USMARI chairman associate professor Dr Ungku Mohd Shahrin said as the standard of living improves, people are becoming more aware of the importance of their appearance and are willing to invest to enhance their self-confidence.

Ungku Mohd Shahrin said with this awareness, the research center anticipated that the domestic aesthetic medicine market will grow at a compounded annual growth rate (CAGR) of 18.8 per cent in 2027.

"We have seen a tremendous increase in the market last year at RM468.8 million from RM366.3 million in 2021. Thus, we expect this growth to continue to RM1.03 billion in 2027.

"Mirroring the general upward trend of beauty related expenditure as the consumers readjust to socializing post-Covid 19, we are now in a solid position to rebuild the aesthetic medicine industry," he said.

However, Ungku Mohd Shahrin said while Malaysia boasts numerous certified and highly skilled medical professionals in this arena, it is distressing to note the escalating number of unauthorised and unqualified individuals offering such services and capitalising on this trend.

He urges the Ministry of Health and other relevant authorities to intensify regulations related to this issue and create more public awareness on the importance of seeking the right cosmetic and aesthetic treatments in the country.

"Our collaborative efforts with Kamarizs Medicare today will drive a paradigm shift towards evidence-based practices. I believe this kind of collaboration will also help to create greater public awareness in the aesthetic medicine industry," he added.

Most Popular
Related Article
Says Stories